This study is thus aimed at deciphering a potential mechanism behind glioblastoma resistance to bevacizumab through the CD146/sCD146 signaling axis with the objective to block this escape pathway that hinders the in vivo effectiveness of bevacizumab. Here, MCAM is linked to glioblastoma.